Article Cited by others


Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease

Singh Harmanjit, Grewal Nipunjot, Arora Ekta, Kumar Harish, Kakkar Ashish Kumar

Year : 2016| Volume: 7| Issue : 1 | Page no: 4-9

   This article has been cited by
1 New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins,Gerasimos P Sykiotis,Michel Maillard,Montserrat Fraga,Camillo Ribi,Thierry Kuntzer,Olivier Michielin,Solange Peters,Georges Coukos,Francois Spertini,John A Thompson,Michel Obeid
The Lancet Oncology. 2019; 20(1): e54
[Pubmed]  [Google Scholar] [DOI]
2 Single-cell RNA sequencing identifies inflammatory tissue T cells in eosinophilic esophagitis
Ting Wen,Bruce J. Aronow,Yrina Rochman,Mark Rochman,Kiran KC,Phil J. Dexheimer,Philip Putnam,Vincent Mukkada,Heather Foote,Kira Rehn,Sam Darko,Daniel Douek,Marc E. Rothenberg
Journal of Clinical Investigation. 2019;
[Pubmed]  [Google Scholar] [DOI]
3 Targets of monoclonal antibodies for immunological diseases
Seon Min Yoo,Sung Hyun Chung
Archives of Pharmacal Research. 2018;
[Pubmed]  [Google Scholar] [DOI]
4 Beyond adhesion:emerging roles for integrins in control of the tumor microenvironment
Whitney Longmate,C Michael DiPersio
F1000Research. 2017; 6: 1612
[Pubmed]  [Google Scholar] [DOI]
5 Role of intestinal flora imbalance in pathogenesis of pouchitis
Xiao-Bo Feng,Jun Jiang,Min Li,Gang Wang,Jin-Wei You,Jian Zuo
Asian Pacific Journal of Tropical Medicine. 2016;
[Pubmed]  [Google Scholar] [DOI]


Read this article